Note to Psychiatrists:
®Schizophrenia patients stable (CGI-S ≤3) on Seroquel®

A global medical research study is being conducted to demonstrate that the efficacy of the sustained release formulation (SR) of Seroquel® is not inferior to the immediate-release formulation (IR), and that stability is maintained when switching from Seroquel® IR to SR.

Benefit to your patient:

• A 4-week run-in period will ensure that your patient is clinically stable (dose range of 400 mg to 800 mg/day). Thereafter, the 6-week double-blind phase of the study will begin, where patients will be assigned to treatment either with a fixed dose of quetiapine SR (taken once daily) or IR (taken twice daily).
• As part of the study, Seroquel® IR is available for 6 months after the treatment period for patients doing well.

Please contact one of the following investigators for more information:

• Prof. FY Jeenah (Chris Hani Baragwanath Hospital, Soweto) +27 11 933 9239
• Dr. MYH Moosa (Chris Hani Baragwanath Hospital, Soweto) +27 11 488 3846
• Dr. V Agambaram (Entabeni Hospital, Durban) +27 31 261 9120
• Dr. FA Randeree (Musgrave Park, Durban) +27 31 201 1531
• Dr. M Slabber (Dey Clinic, Pretoria) +27 12 460 3502